secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001999371-25-011053
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q2 net loss $28.3M; cash $125.3M; FDA PDUFA Aug 15 for TNX-102 SL
-----------------------------------------------------------------------

- Net product revenue $2.0M (down from $2.2M YoY); SG&A surged to $16.2M from $7.5M on pre-launch spend.
- Cash $125.3M at June 30; plus $51.5M raised in Q3 2025; runway into Q3 2026.
- FDA PDUFA date Aug 15, 2025 for TNX-102 SL (fibromyalgia); Fast Track designation.
- First patient dosed in DoD-funded OASIS trial of TNX-102 SL for acute stress reaction.
- Appointed Joseph Hand as General Counsel and James Hunter to board; added to Russell 2000/3000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/0001999371-25-011053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/tnxp-8k_081125.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-011053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer